Sire Bioscience Inc’s (
CSE.SIRE,
OTC: BLLXF,
Forum) business model is based on their ability to engage in the investment, production, and sale of hemp for CBD extraction. That’s the desirable scalable endgame for any cannabis company.
Sire is not in the THC business. The Company is in the health & wellness component of the space.
Sire says their goal is to become a fully vertically-integrated consumer packaged goods life science company with their House of Brands offerings. The Company is headquartered in Toronto Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, logistics, and renewable energy.
In this engaging and entertaining podcast, Stockhouse Media's Dave Jackson was joined by company CEO and COO, Brian Polla, to discuss new company developments, especially in the wake of the COVID-19, how Sire plans to become a disrupter in what Merrill-Lynch predicts to be a “$2.6 trillion CBD space”, and what being a brand-focused CBD / hemp and nutraceuticals company is all about.
FULL DISCLOSURE: This is a paid article of Stockhouse Publishing.